Further trials comparing aspirin with newer anticoagulants (dabigatran, apixaban and rivaroxaban) are necessary to assess the role of each agent in stroke prevention in patients with AF.

Two Phase III trials found that apixaban was more effective for stroke prevention than either aspirin or warfarin in patients with atrial fibrillation (AF), with a similar (versus aspirin ...

Our study is a step toward developing evidence-based clinical guidance to suggest apixaban as a safer choice than warfarin or rivaroxaban in the older AF population with HIV," the authors wrote.

A new study from the University of Bath has found that for older adults with atrial fibrillation (AF), stopping blood ...

In this randomized controlled trial, among patients with atrial fibrillation requiring anticoagulation therapy, asundexian ...

PRESTIGE-AF is the first of the larger trials in this scenario to report results. More data are needed to help guide ...

The OCEANIC-AF is comparing asundexian to Pfizer and Bristol-Myers Squibb’s widely-used oral Factor Xa inhibitor Eliquis (apixaban) in AF patients at risk of a stroke, to see how well they ...

Wang and colleagues say their data build on prior studies, including a network meta-analysis of AF trials that showed excess major bleeding with rivaroxaban compared with apixaban and edoxaban ...

Apixaban and dabigatran ... DOACs lower stroke, raise hemorrhage risk in those with prior brain hemorrhage plus AF The benefit of direct oral anticoagulants on stroke risk in patients with ...

Apixaban is currently the most prescribed oral anticoagulant in the general population and in people with HIV. For people with HIV and atrial fibrillation (Afib or AF), certain oral anticoagulants ...